Drugs / hCT-MSC
hCT-MSC
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04484077 | Jan 2022 → Apr 2024 | autism | Joanne Kurtzberg, MD | Completed | No outcome recorded |
| Phase 1 | NCT04294290 | Feb 2021 → Aug 2022 | autism spectrum disorder | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT03635450 | Dec 2018 → Jul 2019 | perinatal asphyxia | Joanne Kurtzberg, MD | Completed | No outcome recorded |
| Phase 1 | NCT03099239 | Jun 2017 → Jun 2019 | autism | Joanne Kurtzberg, MD | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hCT-MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03099239 ↗ |
| Known as | hCT-MSCs | “hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.” NCT03099239 ↗1“hCT-MSCs are manufactured from umbilical cord tissue donated by healthy mothers delivering full term babies via Cesarean Section.” NCT04484077 ↗ |
| Known as | Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells | “Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC)” NCT04484077 ↗ |
| Modality | Cell therapy | “hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue” NCT03099239 ↗ |
| Route | Intravenous | “one, two, and three intravenous infusions of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC)” NCT03099239 ↗ |